Stocksigma LogoStocksigma Logo

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million

Evonile Pharma Limited (formerly Novartis India Limited) announced that its Board of Directors approved raising funds up to ₹9,000 million via a Rights

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million

Novartis India Ltd · Outcome · 09 Oct 2026, 12:31 am

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) announced that its Board of Directors approved raising funds up to ₹9,000 million via a Rights Issue on 8th Oct'26. The capital raise will involve partly paid-up equity shares with a face value of ₹5 each, subject to statutory and shareholder approvals via postal ballot. The Board constituted a Rights Issue Committee to finalize key terms, including issue size, entitlement ratio, pricing, and record date.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements